BRPI0719732A2 - nanopartículas de peptídeo e usos para as mesmas - Google Patents

nanopartículas de peptídeo e usos para as mesmas

Info

Publication number
BRPI0719732A2
BRPI0719732A2 BRPI0719732A BRPI0719732A BRPI0719732A2 BR PI0719732 A2 BRPI0719732 A2 BR PI0719732A2 BR PI0719732 A BRPI0719732 A BR PI0719732A BR PI0719732 A BRPI0719732 A BR PI0719732A BR PI0719732 A2 BRPI0719732 A2 BR PI0719732A2
Authority
BR
Brazil
Prior art keywords
peptide nanoparticles
nanoparticles
peptide
Prior art date
Application number
BRPI0719732A
Other languages
English (en)
Inventor
Edelson Jonathan
Kotyla Timothy
Original Assignee
Anterios Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anterios Inc filed Critical Anterios Inc
Publication of BRPI0719732A2 publication Critical patent/BRPI0719732A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
    • A61Q1/06—Lipsticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
BRPI0719732A 2006-12-01 2007-11-30 nanopartículas de peptídeo e usos para as mesmas BRPI0719732A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87220606P 2006-12-01 2006-12-01
PCT/US2007/086040 WO2008140594A2 (en) 2006-12-01 2007-11-30 Peptide nanoparticles and uses therefor

Publications (1)

Publication Number Publication Date
BRPI0719732A2 true BRPI0719732A2 (pt) 2017-05-16

Family

ID=40002812

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719732A BRPI0719732A2 (pt) 2006-12-01 2007-11-30 nanopartículas de peptídeo e usos para as mesmas

Country Status (12)

Country Link
US (5) US20100172943A1 (pt)
EP (1) EP2091516A2 (pt)
JP (2) JP5292304B2 (pt)
KR (2) KR20150028308A (pt)
CN (1) CN107080703A (pt)
AU (1) AU2007353340A1 (pt)
BR (1) BRPI0719732A2 (pt)
CA (1) CA2671133C (pt)
IL (2) IL199041A (pt)
MX (1) MX2009005726A (pt)
SG (2) SG179457A1 (pt)
WO (1) WO2008140594A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US20110206739A1 (en) * 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
KR101848095B1 (ko) * 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
EP2394666A2 (en) * 2009-02-05 2011-12-14 Digna Biotech, S.L. Pharmaceutical compositions comprising tgf- beta 1 inhibitor peptides
CN102395598B (zh) * 2009-04-17 2014-07-30 利普泰股份公司 用于治疗和/或护理皮肤和/或毛发的肽、及其在化妆用组合物或药物组合物中的用途
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
US20120328701A1 (en) * 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
JP2014503587A (ja) * 2011-01-24 2014-02-13 アンテリオス， インコーポレイテッド 界面活性剤組成物
BR112013018918A2 (pt) 2011-01-24 2016-10-04 Anterios Inc composições de nanopartículas
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
US9078818B1 (en) 2011-04-29 2015-07-14 Michael Mark Anthony Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution
US8795643B1 (en) * 2011-04-29 2014-08-05 Michael Mark Anthony Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution
CN103764668B (zh) 2011-07-09 2016-08-17 加利福尼亚大学董事会 白血病干细胞靶向配体及应用方法
US9493760B2 (en) 2011-09-08 2016-11-15 The Regents Of The University Of California Fungal-specific metalloproteases and uses thereof
US9554995B2 (en) 2012-06-13 2017-01-31 The University Of Queensland Nanoemulsions
EP3411012A4 (en) 2016-02-04 2019-08-28 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE
US10583199B2 (en) * 2016-04-26 2020-03-10 Northwestern University Nanocarriers having surface conjugated peptides and uses thereof for sustained local release of drugs
MX2019005833A (es) 2016-11-21 2019-10-30 Eirion Therapeutics Inc Administracion transdermica de agentes grandes.
CN110121330B (zh) 2016-12-21 2022-04-29 联合利华知识产权控股有限公司 具有包含4-取代的间苯二酚和氨基酸的谷胱甘肽前体的个人护理组合物
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
EP3558243B1 (en) 2016-12-21 2022-10-05 Unilever IP Holdings B.V. Personal care compositions comprising poorly soluble compounds
PH12019501354B1 (en) 2016-12-21 2023-04-19 Unilever Ip Holdings B V Personal care compositions with cystine
KR102087123B1 (ko) * 2017-04-21 2020-03-10 유씨엘 주식회사 펩타이드와 해조류 추출물을 함유하는 나노에멀젼 및 그를 이용한 화장료 조성물
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
KR102293250B1 (ko) * 2017-09-18 2021-08-26 애니젠 주식회사 활성물질-헥사펩타이드 복합체 및 이를 포함하는 화장료 조성물
ES2726000A1 (es) * 2018-03-28 2019-10-01 Infinitec Activos S L Nanopartículas de oro y palmitoíl pentapéptido-4
US11540984B2 (en) * 2018-05-23 2023-01-03 Conopco, Inc. Nanoemulsions and a method for making the same
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
US20220061315A1 (en) * 2020-08-26 2022-03-03 Simply Pure, LLC Persistent sanitizer
CN112587650A (zh) * 2021-01-19 2021-04-02 中日友好医院(中日友好临床医学研究所) 一种短肽及其铜离子螯合物的医药用途
AU2023270264B2 (en) * 2021-05-19 2025-05-15 Landa Labs (2012) Ltd. Topical compositions and methods of preparing the same
GB2606739A (en) * 2021-05-19 2022-11-23 Landa Labs 2012 Ltd Method of preparing dermatological compositions
WO2024013694A1 (en) * 2022-07-13 2024-01-18 Landa Labs (2012) Ltd. Compositions comprising surface modified globular nano-particles
AU2025200194B2 (en) * 2022-07-13 2026-02-12 Landa Labs (2012) Ltd. Compositions comprising surface modified globular nano-particles
EP4622628A1 (en) * 2022-11-22 2025-10-01 Landa Labs (2012) Ltd. Use of nano-carriers for delivery of active agents
TWI826233B (zh) * 2023-01-10 2023-12-11 台灣中油股份有限公司 葡萄糖胺衍生物奈米微粒及其製備方法與用途

Family Cites Families (214)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172149A (en) 1978-01-30 1979-10-23 Westwood Pharmaceuticals, Inc. Method for treating living skin exhibiting excessive sebum secretion
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
JPS59102091U (ja) 1982-12-24 1984-07-10 株式会社学習研究社 折畳用ゲームボードを備えたゲーム装置
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
JPH0798740B2 (ja) 1987-10-28 1995-10-25 日本新薬株式会社 薬物担体
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5008110A (en) * 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
CH677886A5 (pt) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
HK1001951A1 (en) * 1991-05-03 1998-07-24 Raisio Benecol Ltd. A substance for lowering high cholesterol level in serum and a method for preparing the same
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US6010715A (en) * 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
EP0571677A1 (en) 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
EP0572080B1 (en) 1992-05-29 1995-11-15 Quest International B.V. Aqueous perfume oil microemulsions
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
CA2160681A1 (en) 1993-04-19 1994-10-27 Masao Takahashi Microemulsion preparation containing a slightly absorbable substance
JPH072689A (ja) * 1993-04-19 1995-01-06 Advanced Sukin Res Kenkyusho:Kk 難吸収性物質を含有するマイクロエマルション製剤
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
FI963297L (fi) 1994-02-25 1996-10-18 Takeda Chemical Industries Ltd Antifungaalisia triatsolijohdannaisia sisältävät emulsiot
JPH07285863A (ja) 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (es) 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
US5843334A (en) 1994-06-20 1998-12-01 Nippon Shinyaku Co., Ltd. Method of producing emulsions and an emulsification apparatus
US5672358A (en) 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (fr) * 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5660858A (en) * 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US20010051131A1 (en) * 1996-06-19 2001-12-13 Evan C. Unger Methods for delivering bioactive agents
FR2755854B1 (fr) * 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
EP1921902B1 (en) 1996-12-19 2011-03-02 Ibiden Co., Ltd. Multilayered printed circuit board
FR2760970B1 (fr) * 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US5994414A (en) 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
GB9708066D0 (en) * 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
KR20010041623A (ko) 1998-03-05 2001-05-25 니뽄 신야쿠 가부시키가이샤 흡입 투여용 지방 유제
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
ATE372377T1 (de) * 1998-03-30 2007-09-15 Mibelle Ag Cosmetics Verwendung von nanoemulsionen zur bestimmung der biokompatibilität von lipophilen stoffen im zellkultur-test und dafür geeignete nanoemulsionen
FI111513B (fi) * 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
US7220427B2 (en) * 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
FR2783169B1 (fr) 1998-09-15 2001-11-02 Sederma Sa Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution)
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
FR2787728B1 (fr) * 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
FR2788007B1 (fr) * 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
NZ515644A (en) 1999-06-04 2004-12-24 Skyepharma Inc Oil-core compositions for the sustained release of hydrophobic drugs
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
AU7271800A (en) 1999-08-04 2001-03-05 Idea Ag Periodic structures comprising lipids, polyelectrolytes, and structure-inducing soluble oligovalent linkers, and biological use thereof
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6898427B1 (en) 1999-12-29 2005-05-24 Bellsouth Intellectual Property Corporation Method of coupling portable communications device to first network by way of second network
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
FR2804015B1 (fr) 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
AU2001245947A1 (en) 2000-03-23 2001-10-03 Collaborative Technologies, Inc Method for preparing high pressure/high shear dispersions containing physiologically active ingredients
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809112B1 (fr) 2000-05-16 2004-05-07 Centre Nat Rech Scient Materiaux a base de polymeres biodegradables et son procede de preparation
FR2809010B1 (fr) 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20020155084A1 (en) 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
FR2811561B1 (fr) * 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6455058B1 (en) 2000-09-13 2002-09-24 Amitee Cosmetics, Inc. Composition and method for hair and scalp treatment
FR2816949B1 (fr) * 2000-11-17 2003-11-28 Centre Nat Rech Scient Copolymere a structure sequencee compose d'un segment saccharidique lie a au moins un segment hydrophobe bioerodable, et particules correspondantes
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
DE60130791T2 (de) * 2000-12-27 2008-07-17 Ares Trading S.A. Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
FR2819427B1 (fr) * 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
EP1377255A4 (en) 2001-03-30 2008-11-19 Color Access Inc NEW NANOEMULSIONS
KR100463167B1 (ko) * 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
JP2006512401A (ja) 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
DK1411978T3 (da) 2001-07-27 2009-01-05 Univ Louisiana State Botulinum-toksin ved behandlingen eller forebyggelsen af acne
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US7235230B2 (en) * 2001-10-24 2007-06-26 Clariant Finance (Bvi) Limited Leave-on compositions for personal care
US20030077240A1 (en) * 2001-10-24 2003-04-24 Clariant International, Ltd. Use of high-purity phenylsilsesquioxane liquids for the preparation of cosmetic and pharmaceutical compositions
AU2002333155A1 (en) * 2001-10-30 2003-05-12 Pentapharm Ag Dermopharmaceutically and cosmetically active oligopeptides
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6623780B1 (en) 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
WO2003092585A2 (en) 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
EP1531859A4 (en) * 2002-05-31 2005-12-07 Univ Jefferson COMPOSITIONS AND METHODS FOR TRANSEPITHELIAL MOLECULAR TRANSPORT
US20030224020A1 (en) 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
US20050214378A1 (en) * 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
US6996748B2 (en) * 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
DE10238649A1 (de) * 2002-08-23 2004-03-11 Beiersdorf Ag Dünnflüssige kosmetische oder dermatologische Zubereitungen von Typ Öl-in Wasser
US6864336B2 (en) * 2002-09-12 2005-03-08 3M Innovative Properties Company Fluoroelastomers having low temperature characteristics and solvent resistance
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
DE10258960A1 (de) * 2002-12-16 2004-07-01 Henkel Kgaa Nanoskalige Hydrogele gegen Falten, raue und trockene Haut
KR20050094817A (ko) 2002-12-20 2005-09-28 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. 개선된 약제학적 보툴리늄 독소 조성물
FR2849375B1 (fr) * 2002-12-30 2006-10-20 Jean Noel Thorel Compositions cosmetiques, par exemple pour traiter le vieillissement cutane photo-induit
WO2004078162A1 (en) 2003-01-31 2004-09-16 Elan Pharma International Ltd. Nanoparticulate topiramate formulations
US20060165657A1 (en) * 2003-02-05 2006-07-27 Paul Bernasconi Method for delivery of cosmetic by topical application
EP1599213A4 (en) 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2004084839A2 (en) 2003-03-24 2004-10-07 Cady Roger K Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US20050079228A1 (en) * 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
AU2004273779B2 (en) 2003-06-04 2009-10-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US7419996B2 (en) * 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
CH715855B1 (de) * 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
JP2006199589A (ja) * 2003-09-03 2006-08-03 Ltt Bio-Pharma Co Ltd 生理活性タンパク質またはペプチドを含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる外用剤
WO2005042539A1 (en) * 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
EP1686957B1 (en) * 2003-11-17 2012-03-07 Sederma Compositions containing mixtures of tetrapeptides and tripeptides
NO20035681D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av lungekreft
US20050136024A1 (en) * 2003-12-22 2005-06-23 Stockel Richard F. Dermatological compositions
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
ATE489942T1 (de) 2004-01-23 2010-12-15 Camurus Ab Ternäre nichtlamellare lipidzusammensetzungen
CA2557261A1 (en) 2004-02-23 2005-09-15 The Texas A&M University System Antioxidant compositions and methods of use thereof
DE102004009287A1 (de) 2004-02-26 2005-09-15 Institut Für Neue Materialien Gem. Gmbh Amphiphile Nanopartikel
BRPI0508410B8 (pt) 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
US20050214325A1 (en) 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
DE102004016710B4 (de) 2004-04-05 2020-11-19 Greppmayr GmbH Formulierung zur Fußpflege
EP1586336A1 (en) 2004-04-06 2005-10-19 JOHNSON & JOHNSON GmbH Compositions containing copper salts and soy products
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
EP2266599B1 (en) * 2004-07-26 2014-04-16 Merz Pharma GmbH & Co. KGaA Therapeutic composition with a botulinum neurotoxin
KR100623013B1 (ko) 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US20060084353A1 (en) * 2004-10-18 2006-04-20 Wong Tak K Reversible ball having hyper-elastic properties
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
PT1853303E (pt) 2005-02-14 2016-03-23 Dpm Therapeutics Corp Composições estabilizadas para administração tópica, e métodos para a sua preparação
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP4444149B2 (ja) 2005-03-30 2010-03-31 株式会社ナリス化粧品 超微細エマルジョンで構成される皮膚外用剤
EP2248534A1 (en) 2005-06-14 2010-11-10 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20080274195A1 (en) 2005-07-18 2008-11-06 University Of Massachusetts Lowell Compositions and Methods for Making and Using Nanoemulsions
EP1951200A2 (en) * 2005-08-09 2008-08-06 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20090306198A1 (en) 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
DE102006046076A1 (de) * 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
CN101340884A (zh) 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
WO2007099410A2 (en) * 2005-11-09 2007-09-07 Hormos Medical Ltd. Formulations of fispemifene
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
KR102110379B1 (ko) * 2005-12-01 2020-05-14 유니버시티 오브 메사츄세츠 로웰 보툴리눔 나노에멀젼
CN101374860A (zh) * 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US20070178121A1 (en) 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
EP1998742A2 (en) 2006-03-08 2008-12-10 Nuviance, INC. Transdermal drug delivery compositions and topical compositions for application on the skin
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20070253914A1 (en) * 2006-04-28 2007-11-01 Ha Robert B K Method of exfoliation
US20070274932A1 (en) * 2006-05-15 2007-11-29 The Procter & Gamble Company Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
US8586541B2 (en) * 2006-06-01 2013-11-19 Therapeutic Peptides, Inc. Polymeric biosurfactants
WO2007149868A2 (en) 2006-06-20 2007-12-27 The Regents Of The University Of California Controlled release encapsulated anti-bacterial and anti-inflammatory nanoparticles
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2009007785A2 (en) 2006-11-14 2009-01-15 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
SG177184A1 (en) 2006-12-01 2012-01-30 Anterios Inc Amphiphilic entity nanoparticles
SG179457A1 (en) 2006-12-01 2012-04-27 Anterios Inc Peptide nanoparticles and uses therefor
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US20110206739A1 (en) 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
US20110206736A1 (en) 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same
US20100137357A1 (en) * 2008-11-26 2010-06-03 Koleng John J Compositions and methods for hyperhidrosis
WO2010087964A2 (en) 2009-01-28 2010-08-05 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
US20120328701A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
KR20140016275A (ko) 2011-01-24 2014-02-07 안테리오스, 인코퍼레이티드 비어있는 나노입자의 조성물 및 피부 질환을 치료하기 위한 그의 용도

Also Published As

Publication number Publication date
US20220175634A1 (en) 2022-06-09
US20170079895A1 (en) 2017-03-23
IL247617A0 (en) 2016-11-30
EP2091516A2 (en) 2009-08-26
US20100172943A1 (en) 2010-07-08
SG179457A1 (en) 2012-04-27
US9486409B2 (en) 2016-11-08
CN101917959A (zh) 2010-12-15
KR20090098970A (ko) 2009-09-18
AU2007353340A1 (en) 2008-11-20
US20140234382A1 (en) 2014-08-21
US20210308021A1 (en) 2021-10-07
CN107080703A (zh) 2017-08-22
JP2013199487A (ja) 2013-10-03
IL199041A (en) 2016-09-29
JP2011502952A (ja) 2011-01-27
KR101518077B1 (ko) 2015-05-28
KR20150028308A (ko) 2015-03-13
SG10201607909WA (en) 2016-11-29
WO2008140594A3 (en) 2010-03-25
CA2671133C (en) 2015-11-24
US10905637B2 (en) 2021-02-02
MX2009005726A (es) 2009-09-28
CA2671133A1 (en) 2008-11-20
JP5292304B2 (ja) 2013-09-18
WO2008140594A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0719732A2 (pt) nanopartículas de peptídeo e usos para as mesmas
NO2022027I1 (no) Combination of daunorubicin and cytarabine
BRPI0922486A2 (pt) microcápsulas e suas respectivas utilizações
CY2015013I1 (el) Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων
BRPI0717638A2 (pt) Anticorpors e imunoconjugados e usos para os mesmos
DE602007010795D1 (de) Blattsauger und -häcksler
BRPI0907064A2 (pt) "métodos e sistemas"
PT2029145T (pt) Compostos pirrolopirimidina e suas utilizações
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0717339A2 (pt) Reversor de empuxo e nacela de turboélice
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0716300A2 (pt) Artigo e mistura
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI0812747A2 (pt) Sistema para tratamento de mechas de cabelo
BRPI0822296A2 (pt) Transponder e livreto
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
DK2068886T3 (da) Lipidholdige præparater
BRPI0922790A2 (pt) peptídeos de ligação sparc e usos dos mesmos
BRPI0819573A2 (pt) Composição e artigo
HRP20170698T1 (hr) Lizosomski usmjereni peptidi i njihove uporabe
BRPI0717389A2 (pt) Dispositivos e métodos para avanço de stent
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0822221A2 (pt) Composições aquosas e estáveis de ciclosporina
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]